Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Organ-Derived Decellularized Extracellular Matrix: A Game Changer for Bioink Manufacturing?

Choudhury D, Tun HW, Wang T, Naing MW.

Trends Biotechnol. 2018 Apr 18. pii: S0167-7799(18)30087-8. doi: 10.1016/j.tibtech.2018.03.003. [Epub ahead of print] Review.

PMID:
29678431
2.

Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy.

von Roemeling CA, Caulfield TR, Marlow L, Bok I, Wen J, Miller JL, Hughes R, Hazlehurst L, Pinkerton AB, Radisky DC, Tun HW, Kim YSB, Lane AL, Copland JA.

Oncotarget. 2017 Oct 6;9(1):3-20. doi: 10.18632/oncotarget.21545. eCollection 2018 Jan 2.

3.

Pharmacokinetics-based clinical management of acquired von Willebrand syndrome: a case report.

Baldeo CM, Rivera CE, Tun HW, Vishnu P.

J Blood Med. 2018 Jan 19;9:9-13. doi: 10.2147/JBM.S152663. eCollection 2018.

4.

Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.

Qiu Y, Li Z, Pouzoulet F, Vishnu P, Copland JA 3rd, Knutson KL, Soussain C, Tun HW.

Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.15009. [Epub ahead of print] No abstract available.

PMID:
29076134
5.

Hairy Cell Lymphoma: A Potentially Under-Recognized Entity.

Hammond WA, Swaika A, Menke D, Tun HW.

Rare Tumors. 2017 Mar 28;9(1):6518. doi: 10.4081/rt.2017.6518. eCollection 2017 Mar 24.

6.

Mantle cell lymphoma with a novel t(11;12)(q13;p11.2): a proposed alternative mechanism of CCND1 up-regulation.

Menke JR, Vasmatzis G, Murphy S, Yang L, Menke DM, Tun HW, King RL, Smoley SA, Ketterling RP, Sukov WR.

Hum Pathol. 2017 Jun;64:207-212. doi: 10.1016/j.humpath.2017.01.001. Epub 2017 Jan 27.

PMID:
28132860
7.

Compounds, compositions, and methods of agelastatin alkaloids: patent evaluation of WO2015042239 (A1).

Yoshimitsu T, Tun HW.

Expert Opin Ther Pat. 2017 Feb;27(2):113-119. doi: 10.1080/13543776.2017.1273902. Epub 2017 Jan 5.

PMID:
28056571
8.

Corrigendum: Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes.

Qie Y, Yuan H, von Roemeling CA, Chen Y, Liu X, Shih KD, Knight JA, Tun HW, Wharen RE, Jiang W, Kim BY.

Sci Rep. 2016 Aug 1;6:30663. doi: 10.1038/srep30663. No abstract available.

9.

Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes.

Qie Y, Yuan H, von Roemeling CA, Chen Y, Liu X, Shih KD, Knight JA, Tun HW, Wharen RE, Jiang W, Kim BY.

Sci Rep. 2016 May 19;6:26269. doi: 10.1038/srep26269. Erratum in: Sci Rep. 2016 Aug 01;6:30663.

10.

Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma.

Yushi Q, Li Z, Von Roemeling CA, Doeppler H, Marlow LA, Kim BY, Radisky DC, Storz P, Copland JA, Tun HW.

Oncotarget. 2016 May 31;7(22):32156-71. doi: 10.18632/oncotarget.8537.

11.

T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Presenting as a Primary Central Nervous System Lymphoma.

Advani P, Starr J, Swaika A, Jiang L, Qiu Y, Li Z, Tun HW.

Rare Tumors. 2015 Dec 29;7(4):6084. doi: 10.4081/rt.2015.6084. eCollection 2015 Dec 29.

12.

Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

Gupta E, Accurso J, Sluzevich J, Menke DM, Tun HW.

Rare Tumors. 2015 Dec 29;7(4):6067. doi: 10.4081/rt.2015.6067. eCollection 2015 Dec 29.

13.

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.

Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, Macon W, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic S, Nowakowski GS, Gupta M.

Blood. 2015 Jul 16;126(3):328-35. doi: 10.1182/blood-2015-02-629543. Epub 2015 Apr 28.

14.

Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.

von Roemeling CA, Marlow LA, Pinkerton AB, Crist A, Miller J, Tun HW, Smallridge RC, Copland JA.

J Clin Endocrinol Metab. 2015 May;100(5):E697-709. doi: 10.1210/jc.2014-2764. Epub 2015 Feb 12.

15.

S100A8 is a novel therapeutic target for anaplastic thyroid carcinoma.

Reeb AN, Li W, Sewell W, Marlow LA, Tun HW, Smallridge RC, Copland JA, Spradling K, Chernock R, Lin RY.

J Clin Endocrinol Metab. 2015 Feb;100(2):E232-42. doi: 10.1210/jc.2014-2988. Epub 2014 Nov 25.

16.

Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration.

Von Roemeling CA, Marlow LA, Radisky DC, Rohl A, Larsen HE, Wei J, Sasinowska H, Zhu H, Drake R, Sasinowski M, Tun HW, Copland JA.

Oncotarget. 2014 Jul 30;5(14):5320-34.

17.

Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4.

von Roemeling CA, Radisky DC, Marlow LA, Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW, Copland JA.

Cancer Res. 2014 Sep 1;74(17):4796-810. doi: 10.1158/0008-5472.CAN-14-0210. Epub 2014 Jun 24.

18.

Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.

Li Z, Qiu Y, Personett D, Huang P, Edenfield B, Katz J, Babusis D, Tang Y, Shirely MA, Moghaddam MF, Copland JA, Tun HW.

PLoS One. 2013 Aug 5;8(8):e71754. doi: 10.1371/journal.pone.0071754. Print 2013.

19.

CD47 and osteopontin expression in diffuse large B-cell lymphoma with nodal and intravascular involvement.

Starr JS, Jiang L, Li Z, Qiu Y, Menke DM, Tun HW.

Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):597-601. doi: 10.1016/j.clml.2013.05.001. Epub 2013 Jun 26. No abstract available.

PMID:
23810243
20.

Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.

von Roemeling CA, Marlow LA, Wei JJ, Cooper SJ, Caulfield TR, Wu K, Tan WW, Tun HW, Copland JA.

Clin Cancer Res. 2013 May 1;19(9):2368-80. doi: 10.1158/1078-0432.CCR-12-3249. Epub 2013 Apr 30.

21.

Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).

Shanafelt TD, Ramsay AG, Zent CS, Leis JF, Tun HW, Call TG, LaPlant B, Bowen D, Pettinger A, Jelinek DF, Hanson CA, Kay NE.

Blood. 2013 May 16;121(20):4137-41. doi: 10.1182/blood-2012-12-470005. Epub 2013 Mar 14.

22.

A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin.

Larsen JT, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Wu W, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ, Litzow MR.

Leuk Lymphoma. 2013 Aug;54(8):1713-8. doi: 10.3109/10428194.2012.753444. Epub 2012 Dec 31.

PMID:
23189958
23.

Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.

Cooper SJ, von Roemeling CA, Kang KH, Marlow LA, Grebe SK, Menefee ME, Tun HW, Colon-Otero G, Perez EA, Copland JA.

Mol Cancer Ther. 2012 Oct;11(10):2105-15. doi: 10.1158/1535-7163.MCT-11-0873. Epub 2012 Jul 23.

24.

Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies.

Marlow LA, von Roemeling CA, Cooper SJ, Zhang Y, Rohl SD, Arora S, Gonzales IM, Azorsa DO, Reddi HV, Tun HW, Döppler HR, Storz P, Smallridge RC, Copland JA.

J Cell Sci. 2012 Sep 15;125(Pt 18):4253-63. doi: 10.1242/jcs.097428. Epub 2012 Jun 20.

25.

Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma.

Jiang L, Li Z, Finn LE, Personnet DA, Edenfield B, Foran JM, Jaeckle KA, Reimer R, Menke DM, Ketterling RP, Tun HW.

Int J Clin Exp Pathol. 2012;5(1):72-6. Epub 2012 Jan 1.

26.

Plasmacytoma-like posttransplant lymphoproliferative disorder following orthotopic liver transplantation: a case report.

Vishnu P, Jiang L, Cortese C, Menke DM, Tun HW.

Transplant Proc. 2011 Sep;43(7):2806-9. doi: 10.1016/j.transproceed.2011.07.004.

PMID:
21911168
27.

Hypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines.

Khurana A, Tun HW, Marlow L, Copland JA, Dredge K, Shridhar V.

Mol Carcinog. 2012 Jul;51(7):565-75. doi: 10.1002/mc.20824. Epub 2011 Jul 7.

28.

Selective central nervous system tropism of primary central nervous system lymphoma.

Jiang L, Marlow LA, Cooper SJ, Roemeling CV, Menke DM, Copland JA, Tun HW.

Int J Clin Exp Pathol. 2010 Oct 8;3(8):763-7.

29.

Molecular analysis of intravascular large B-cell lymphoma with neoangiogenesis.

Saurel CA, Personett DA, Edenfield BH, Solberg LA, Jiang L, Menke DM, Tun HW.

Br J Haematol. 2011 Jan;152(2):234-6. doi: 10.1111/j.1365-2141.2010.08354.x. Epub 2010 Oct 19. No abstract available.

PMID:
20955396
30.

Pathway signature and cellular differentiation in clear cell renal cell carcinoma.

Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ, Copland JA.

PLoS One. 2010 May 18;5(5):e10696. doi: 10.1371/journal.pone.0010696.

31.

Use of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphoma.

Shetty RK, Adams BH, Tun HW, Runyan BR, Menke DM, Broderick DF.

Ocul Immunol Inflamm. 2010 Apr;18(2):110-2. doi: 10.3109/09273940903450313.

PMID:
20370339
32.

Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

Cooper SJ, Zou H, Legrand SN, Marlow LA, von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V, Tun HW, Blobe GC, Wood CG, Copland JA.

Oncogene. 2010 May 20;29(20):2905-15. doi: 10.1038/onc.2010.64. Epub 2010 Mar 8.

33.

Pathway analysis of primary central nervous system lymphoma.

Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P, Edenfield B, Zubair AC, O'Neill BP, Lai WR, Park PJ, McKinney M.

Blood. 2008 Mar 15;111(6):3200-10. doi: 10.1182/blood-2007-10-119099. Epub 2008 Jan 9.

34.

Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide.

Zou YS, Fink SR, Stockero KJ, Paternoster SF, Smoley SA, Tun HW, Reeder CB, Tefferi A, Dewald GW.

Leuk Res. 2007 Sep;31(9):1185-9. Epub 2006 Nov 27.

PMID:
17125835
35.

Etanercept therapy for late-onset idiopathic pneumonia syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation.

Tun HW, Wallace KH, Grinton SF, Khoor A, Burger CD.

Transplant Proc. 2005 Dec;37(10):4492-6.

PMID:
16387152

Supplemental Content

Support Center